Interferon Gamma 1b as a treatment for macular edema caused by uveitis

Phase 2

Conditions: veitic cystoid macular edema.
other specified retinal disorders, uveitis
H35.8, H20

Registration Number: IRCT201105236568N1

Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 10

Inclusion Criteria

(to have medial, posterior or pan-uveitis at least 3 months before the participation in the study together with macular cystoid edema secondary to uveitis in at least one eye; to have visual acuity equal or greater than 20/200; to be 18 to 60 year-old; to have a central macular thickness greater than 250 micrometers)
Exclusion criteria: (pregnancy or breast feeding; occurrence of intolerable adverse effects; to have a history of herpetic kerititis and multiple sclerosis; to have an active infection which needs an urgent treatment; history of chronic or recurrent infections)

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Central Macular Thickness. Timepoint: Before the initiation of the intervention, one week after instillation of each dose for 3 weeks, 3 months after the finishing of the study. Method of measurement: Using Optical Coherence Tomography (OCT), micrometer.;Intraoccular pressure. Timepoint: Before the initiation of the intervention, one week after instillation of each dose for 3 weeks, 3 months after the finishing of the study. Method of measurement: Using tonometer, mmHg.;Intraoccular inflammation. Timepoint: Before the initiation of the intervention, one week after instillation of each dose for 3 weeks, 3 months after the finishing of the study. Method of measurement: Using slit lamp, mild or moderate or severe.

Secondary Outcome Measures

Name	Time	Method
Visual acuity. Timepoint: Before the initiation of the intervention, one week after instillation of each dose for 3 weeks, 3 months after the finishing of the study. Method of measurement: Snellen chart, in a fraction of 200.